MCL is a rare and aggressive subtype of non-Hodgkin lymphoma, often diagnosed in later stages and characterised by the malignant transformation of ... "AstraZeneca secures first BTK approval in ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

There are many different types of non-Hodgkin lymphoma and the response of patients to treatment depends largely on the type of lymphoma and the stage ... cell lymphoma, Burkitt’s lymphoma and ...

Many types of leukemia produce no obvious symptoms in the early stages. Leukemia red spots are an early warning sign of leukemia. Symptoms of non-Hodgkin's lymphoma may include painless swelling ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...